The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | GLOW: primary analysis of ibrutinib plus venetoclax versus obinutuzumab plus chlorambucil in CLL
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, shares an update on the randomized Phase III GLOW study (NCT03462719) of fixed-duration ibrutinib and venetoclax versus chlorambucil plus obinutuzumab for the frontline treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL). Prof. Kater gives an overview of the rationale for the trial, discussing synergies between ibrutinib, which inhibits CLL proliferation and mobilization of cells from protective lymphoid niches, and venetoclax, which efficiently kills circulating CLL cells. Prof. Kater also highlights data from other trials including the Phase II VIsion/HO141 trial (NCT03226301), and the Phase II CAPITIVATE study (NCT02910583). Primary analysis of data from the GLOW study demonstrates an improved progression-free survival for patients receiving ibrutinib plus venetoclax versus chlorambucil plus venetoclax with a hazard ratio of 0.2, and benefits observed in all subgroups. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Arnon Kater, MD, PhD, has participated in advisory boards and/or received research grants from Abbvie, BMS, Janssen, Roche/Genentech and Astra Zeneca; and has received speakers fees from Abbvie.
